Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I think I remember that the interim analysis had a slide that said the trial had about two-thirds severe and one-third critical. But maybe I got that ratio from Otto Yang's eINDS. Does anyone know if the ratio of critical and severe was given in the interim analysis?
I'm tempted to buy right now but I keep coming back to Michael Mulholland's stock sell. He liquidated everything right before trial results. Mulholland would not have sold that amount of stock if he believed trial results were going to be good.
CytoDyn chose the members of the DSMB. That must mean that Nader was given the results of the interim analysis, is that correct?
This article is phenomenal! It is such a good, detailed summary of everything. It is the perfect article for people to post on Twitter and other social media. I even emailed it to a friend who has been asking me about RLFTF. Here is the link again: https://www.pharmasalmanac.com/articles/how-an-agile-company-addressed-the-pandemic-moving-from-psychiatric-medicines-to-a-covid-19-therapeutic
CNBC is now showing the low of the day at $.34. They were showing $.08 before. So obviously it was a mistake.
All of the small pharma Covid stocks have small trials. Under normal circumstances, they'd all have to increase their enrollment numbers to get an EUA. But we are in a pandemic with a huge need for a Covid therapeutic that treats the serious cases. An EUA from a trial of 165 is possible if they have very impressive data. The same goes for HGEN and CYDY with their small trials. Any of the 3 could get an EUA with less than 500 patients or the FDA might require any or all to proceed with their trials with larger enrollment. No one knows.
In the last couple of weeks, HGEN, CYDY, and RVVTF have all doubled their stock price. RLFTF is the only small pharma Covid stock that hasn't exploded in anticipation of trial results. It will be next. RLFTF's trial results come before the others and RLFTF's anecdotal evidence is better than all.
In the last couple of weeks, HGEN, CYDY, and RVVTF have all doubled their stock price. RLFTF is the only small pharma Covid stock that hasn't exploded in anticipation of trial results. It will be next. RLFTF's trial results come before the others and RLFTF's anecdotal evidence is better than all, including CytoDyn.
In the last couple of weeks, HGEN, CYDY, and RVVTF have all doubled in stock price. RLFTF is the only small pharma Covid stock that hasn't exploded in anticipation of trial results. It will be next. RLFTF's trial results come before the others and RLFTF's anecdotal evidence is better than all.
Some investors who take profits from BRPA will put that money into RLFTF. It's actually surprising that the BRPA runup didn't have a catastrophic effect on RLFTF's stock price. The BRPA money will start coming into RLFTF soon and will keep coming for at least a month.
SPACs are all the rage. But RLFTF's stock price didn't fall and some of the profits made on the BRDA run up will surely come back to RLFTF.
The mainstream media doesn't cover drugs being trialed. We will get plenty of media if an EUA is granted by the FDA. But we need a completed trial. The FDA wants completed studies to give approval. None of the Covid drugs unblinded their data at the interim analysis. Unblinding would have satisfied your curiosity but unblinding would not have helped get FDA approval.
Vanilla, all of the small pharma Covid stocks have those problems. We need data from a completed double blind trial. They announced that the trial was fully enrolled on Dec 8th. That's the only information we need. Now we wait for data. The anecdotal evidence is spectacular. The trial results are far more likely to be good than bad.
HGEN, CYDY, and RVVTF have all had their stock prices rise dramatically recently in anticipation of their trials finishing. RLFTF is the only one left to rise. RLFTF's trial ends first and its anecdotal evidence is as good as any Covid therapeutic. And it's cheap and easy to make while mabs are expensive and difficult to make. It won't be long before RLFTF's stock price rises like the others.
HGEN, CYDY, and RVVTF all had their stock prices rise dramatically recently in anticipation of their trials finishing. RLFTF is the only one left to rise. RLFTF's trial ends first and its anecdotal evidence is as good as any Covid therapeutic. And its cheap and easy to make while mabs are expensive and difficult to make. It won't be long before RLFTF's stock price rises like the others.
HGEN, CYDY, and RVVTF have all had their stock prices rise dramatically recently in anticipation of their trials finishing. RLFTF is the only one left to rise. RLFTF's trial ends first and its anecdotal evidence is as good as any Covid therapeutic. And its cheap and easy to make while mabs are expensive and difficult to make. It won't be long before RLFTF's stock price rises like the others.
It's going to be a bloodbath for the Covid stocks.
I have a theory that they are slow rolling enrollment on purpose. If the DSMB believes that the trial isn't going to fill for a long time, they might be more apt to support an EUA based on the interim. If an EUA isn't granted, I think Nader pays the penalty to unblind the data. Leronlimab will be promoted around the world based on the interim data. We are in a pandemic, people are going to want leronlimab even if the results are marginally good because it is so safe of a drug.
Monoclonal antibodies were also mentioned in today's Senate health committee by Fauci and by Chairman Lamar Alexander. Alexander specifically said that monoclonal cocktails are the most promising.
Chairman Lamar Alexander: "The most promising appear to be monoclonal antibody cocktails, which have been used to prevent and treat other diseases, like Ebola. Three companies are in clinical trials of antibody cocktails."
Anthony Fauci: "You mentioned, appropriately and correctly, that we feel optimistic about monoclonal antibodies, which are currently being tested in an outpatient setting, in an inpatient setting. Family prophylaxis, which means when an individual in a given family gets infected, if you give monoclonal antibodies to the rest of the family, can you prevent the spread within the family unit, and finally nursing home prophylaxis. As you mentioned there are three companies involved in this."
https://www.rev.com/transcript-editor/shared/fSClbKGTnjyrCzRUCOp9-TmCZu6TYquMw3wwFNABsKi8tFTP_ad1UbGibWkEutnNYapPqmTYd7hFQ0JtkblNOSyOKhI?loadFrom=PastedDeeplink&ts=1803.721&hasReloaded=true